SAF, I have plenty of skin in the game as well
Post# of 148294
I have plenty of skin in the game as well. The weight of you argument is not bolstered by an allusion to your
investment.
You argued that there would be no uplist, as there is no FDA approval. Again, I believe that is factually incorrect, regardless of the terms you choose to apply. I have seen NASDAQ criteria for uplist posted here multiple times.
Please show me where FDA approval is listed as a criteria. The concern for the ability of the company to continue as a going concern I believe is addressed by the requirement for cash on hand, which is why the $55m was addressed at the July 22 shareholders' conference call.
There have been many posts about a putative denial of uplisting. I believe those are premature and this is inappropriate to speculate about the causes of an event that has not been demonstrated to have occurred.